Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares November 10, 2025
Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress September 19, 2025
